ADO and neoplasm: Whether used as monotherapies or in combination with other therapeutic agents, current immune-oncological treatments aim to increase the immune response of the host immune system against the tumour mass, mainly by inhibiting ATP hydrolysis to ADO or AR signalling in immune cells.